SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio Inc. (IBRX) is experiencing significant bullish momentum driven by its innovative cancer treatment, Anktiva, following recent global regulatory advancements and ongoing clinical discussions, with many investors anticipating a potential short squeeze fueled by considerable short interest.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical (DRTS) is surging following its Japan PMDA marketing approval for Alpha DaRT and encouraging clinical updates for a second Glioblastoma (GBM) patient. The community is highly bullish, anticipating a significant breakout as institutional interest grows and the company transitions to global commercialization of its physics-based 'universal killer' cancer treatment.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

Starknet is trending due to its relentless technical development, including new SDKs for Web2 integration, compliant institutional privacy solutions, and expanding BTCFi capabilities, alongside a surge in on-chain TradFi markets. The community points to its advanced ZK-STARKs, quantum-resistant design, and high developer activity as reasons why the network's long-term infrastructure value is currently being mispriced.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

Sigma Lithium is trending after UBS significantly increased its lithium price outlook by 74%, fueling community discussions about an impending lithium deficit and potential short squeeze. This bullish sentiment is further supported by the company's sale of high-purity lithium fines at premium prices, consistent insider buying, and active efforts to counter inaccurate media reports.

DHT Holdings, Inc. engages in the operation of a fleet of crude oil tankers. It operates through its integrated management companies in Monaco, Singapore, and Oslo, Norway. The company was founded in 2005 and is headquartered in Hamilton, Bermuda.

DHT Holdings Inc

Surging VLCC spot rates and advantageous long-term charter agreements are fueling community excitement around DHT Holdings, widely regarded as a "profit machine" due to its 100% net income payout policy and low operational breakeven. Discussion centers on how global tariffs are creating a "tonne-mile explosion" and an undersupplied tanker market as trade routes lengthen and the "shadow fleet" faces disruption, positioning DHT for substantial returns.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Axon is experiencing significant upward momentum after its strong earnings report revealed robust revenue growth and an incredibly bullish outlook, fueling community discussions around its successful transition to SaaS and AI-driven solutions as major catalysts for future margins and its "Moonshot" vision.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

WBD is trending as Paramount Skydance's significantly revised all-cash offer, now at $31 per share plus a ticking fee and commitment to cover Netflix's breakup cost, has prompted WBD's board to consider it a potentially superior proposal. The community is sharply divided on whether Netflix will increase its own complex bid or opt to accept the breakup fee amidst mounting regulatory concerns and debt implications.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is a focal point of intense debate, with some traders fearing significant drops amidst broader crypto market corrections and global uncertainties, while a strong contingent sees current levels as a prime "buy the dip" opportunity, highlighting its continued ecosystem growth and high transaction volume.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending as its privacy features gain traction, highlighted by BitMEX co-founder Arthur Hayes including ZEC in his portfolio and the recent favorable conclusion of an SEC investigation. The community is actively discussing these catalysts alongside the launch of a new wallet by the original development team, fueling a renewed interest in privacy-focused cryptocurrencies.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as the bidding war for Warner Bros. Discovery intensifies with Paramount's revised offer, igniting strong community discussion on whether Netflix should raise its bid or walk away to collect a substantial breakup fee, all while facing heightened regulatory and political pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>As part of the settlement, CarMax will pay at least $420,000 in damages to servicemembers and a civil penalty of $79,380 to the United States, the department said.</li><li>The company will further revise its policies and procedures pertaining to the allegations, the department said.</li><li>In the Q3 fiscal year 2026, the company announced that its retail used unit sales fell 8% and comparable store used unit sales declined 9%.</li></ul>Shares of CarMax Inc. (KMX) slumped 5% on Monday after the U.S. Department of Justice announced that it has reached a settlement with the user car retailer.The DOJ <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.justice.gov/opa/pr/carmax-pay-nearly-500000-remedy-illegal-repossessions-us-servicemembers-vehicles#:~:text=As%20part%20of%20the%20settlement,%2479%2C380%20to%20the%20United%20States.">said</a> that the settlement seeks to resolve allegations that CarMax illegally repossessed motor vehicles owned by members of the military without obtaining court orders.A federal law prevents an auto finance or leasing company from repossessing a servicemember’s vehicle without first obtaining a court order, as long as the servicemember made at least one payment on the vehicle before entering military service.As part of the settlement, CarMax will pay at least $420,000 in damages to servicemembers and a civil penalty of $79,380 to the United States, the department said. The company will further &nbsp;revise its policies and procedures pertaining to the allegations, the department added.<h2 class="st-heading-2">Tough Q3, New CEO</h2>CarMax has over 250 stores in 41 states, and has sold over 13 million cars and bought 15 million, as per the company’s website. In the third-quarter (Q3) of fiscal year 2026 ended November, the company announced that its retail used unit sales fell 8% and comparable store used unit sales declined 9%. Net earnings fell to $0.43 per share in the quarter, compared to $0.81 a year ago.Earlier this month, CarMax also appointed Keith Barr, former CEO of InterContinental Hotels Group as President and CEO, effective March 16. Interim CEO David McCreight will transition to his prior duties as an independent Director of the Board, the company said at the time.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around KMX stock stayed within the ‘bearish’ territory while message volume remained at ‘high’ levels.<a href="https://stocktwits.com/symbol/KMX">KMX stock</a> has dropped 49% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/uber-to-allow-parking-reservations-on-app-with-new-acquisition/cZRM2eJR4zb">Uber To Allow Parking Reservations On App With New Acquisition</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Volkswagens and other used vehicles for sale at a CarMax dealership in San Diego, California. (Photo by Kevin Carter/Getty Images)

KMX Stock Slumps On DOJ Settlement Over Military Personnel Vehicle Purchase

The DOJ said that the settlement seeks to resolve allegations that CarMax illegally repossessed motor vehicles owned by members of the military without obtaining court orders.

Equity

<ul class="summary-bullets"><li>If implemented, this change would transition from a mix of local jails and privately operated prisons to a centralized model featuring larger facilities, as per the Bloomberg report.&nbsp;</li><li>A reduction in ICE's network may significantly impact a key revenue source for GEO Group and CoreCivic, who collectively hold about 58% of individuals detained by ICE.</li><li>In 2025, GEO entered into new contracts to house ICE detainees at four facilities totaling approximately 6,000 beds.</li></ul>Shares of GEO Group and CoreCivic fell on Friday on report that Immigration and Customs Enforcement (ICE) is planning to shrink down its network of privately owned detention facilities.Immigration and Customs Enforcement reportedly intends to reduce its network of over 200 detention centers—primarily run by private companies—to only 34 government-owned locations, a change that would impact established private prison corporations such as GEO Group and CoreCivic Inc.If implemented, this change would transition from a mix of local jails and privately operated prisons to a centralized model featuring larger facilities—mainly industrial warehouses—owned by the Department of Homeland Security, according to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-02-19/trump-s-immigration-push-to-warehouses-could-cut-out-corecivic-geogroup">report</a> from Bloomberg News, citing local officials briefed on the plan.<h2 class="st-heading-2">Hit On GEO Group And CoreCivic</h2>A reduction in ICE's network may significantly impact a key revenue source for GEO Group and CoreCivic, who collectively hold about 58% of individuals detained by ICE, as per the report that cited company disclosures.Contracts from ICE account for nearly half of GEO’s projected revenue of $2.9 billion to $3.1 billion for 2026. For CoreCivic, the revenues from ICE accounted for 40% of its entire fourth quarter revenue.&nbsp;In December 2025, GEO Group was awarded a new two-year contract by ICE for the provision of Skip Tracing services. In 2025, GEO entered into new contracts to house ICE detainees at four facilities totaling approximately 6,000 beds, increasing ICE capacity from approximately 20,000 beds to approximately 26,000 beds.&nbsp;ICE will now rely primarily on government-owned facilities but private companies will maintain a role, which may include providing services such as medical care and security, Bloomberg said.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around GEO and CXW trended in ‘bullish’ territory.&nbsp;Shares in GEO and CXW have fallen 52% and 12%, respectively.&nbsp; &nbsp;

 A view of the CoreCivic Otay Mesa Detention Center in San Diego, California, United States on February 07, 2025. 

GEO Group And CoreCivic Stocks Are Getting Beaten Up Today – Why Such A Selloff?

 Immigration and Customs Enforcement reportedly plans to shrink its network of more than 200 detention facilities, according to a Bloomberg News report. 

<ul class="summary-bullets"><li>Corcept’s mifepristone product Korlym was approved by the FDA in 2012 to treat Cushing’s syndrome and subsequently, in 2020, Teva got the agency’s approval to market a generic version of the drug.</li><li>Corcept appealed a decision from the United States District Court for the District of New Jersey finding no infringement of patents but the appeals court affirmed the lower court's ruling.</li><li>The appeals court on Thursday noted that Corcept failed to prove direct infringement. &nbsp;</li></ul> Shares of Corcept Therapeutics (CORT) plunged 15% on Thursday after the United States Court of Appeals for the Federal Circuit issued a ruling backing Teva Pharmaceutics (TEVA) in a patent dispute involving its Korlym tablets.Corcept appealed a decision from the United States District Court for the District of New Jersey finding no infringement of patents, but the appeals court affirmed the lower court's ruling.TEVA shares edged up marginally at the time of writing.&nbsp;<h2 class="st-heading-2">Korlym Patent Fight</h2>Corcept’s mifepristone product Korlym was approved by the U.S. Food and Drug Administration in 2012 to treat Cushing’s syndrome. Subsequently in 2020, Teva got the agency’s approval to market a generic version of the drug to treat the rare, serious endocrine disorder caused by chronic, excessive exposure to high cortisol levels. However, Corcept posited that the generic drug infringes its patents.In 2023, a New Jersey district court ruled that Teva does not infringe upon Corcept’s patents and the company subsequently appealed. The appeals court on Thursday noted that Corcept failed to prove direct infringement. &nbsp;“We perceive no clear error in the district court’s finding—based on “all the relevant evidence”—that Corcept failed to prove that if Teva’s proposed product were marketed, direct infringement would result,” the court<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cafc.uscourts.gov/opinions-orders/24-1346.OPINION.2-19-2026_2649652.pdf"> said.</a> “Because we see no clear error in the district court’s fact findings regarding direct infringement, we need not and do not reach the additional finding of specific intent to induce infringement.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CORT stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘extremely low’ to ‘high’ levels.<a href="https://stocktwits.com/symbol/CORT">CORT stock</a> has lost 54% over the past 12 months while TEVA nearly doubled its value.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/netflix-could-hike-offer-for-wbd-if-paramount-does-report/cZRkEOOR4DO">Netflix Could Hike Offer For WBD If Rival Bidder Paramount Does: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Corcept Therapeutics logo is seen displayed on a smartphone screen. 

CORT Stock Drops After Appeals Court Sides With Teva In Korlym Patent Fight

The ruling pertains to Corcept’s Korlym tablets for the treatment of Cushing syndrome. 

<ul class="summary-bullets"><li>Adjusted net loss per share in the quarter was $0.14, compared to $0.31 in the prior quarter. Analysts on average expected loss per share of $0.22.&nbsp;</li><li>The company said that it expects FY2026 revenues to be within the range of $290 million to $320 million.</li></ul>Solaredge Technologies (<a href="https://stocktwits.com/symbol/SEDG">SEDG</a>) shares were down on Wednesday as its quarterly revenue declined from the year-ago quarter.&nbsp;The company reported revenues of $335.4 million, down 1.4% from $340.2 million in the prior quarter. However, it still beat analyst estimates of $270 million, as per data from fiscal.ai.&nbsp;<h2 class="st-heading-2">Q4 Snapshot</h2>Adjusted net loss per share in the quarter was $0.14, compared to $0.31 in the prior quarter. Analysts on average expected loss per share of $0.22.&nbsp;“We gained momentum last year, delivering strong year-over-year revenue growth and expanding our gross margins in each and every quarter. Our solid fourth quarter results continued this trend,” said Shuki Nir, Chief Executive Officer of Solaredge Technologies.&nbsp;During the quarter, approximately 98.8 thousand inverters, 2.87 million optimizers and 280 MWh of batteries for Photovoltaic (PV) applications were recognized as revenue, the statement said.&nbsp;<h2 class="st-heading-2">Outlook</h2>The company said that it expects FY2026 revenues to be within the range of $290 million to $320 million and said that the range does not include significant one-time or pull forward of revenue.&nbsp;Analysts on average were expecting FY2026 revenue to be $292.2 million.&nbsp;It said it expects adjusted gross margin to be within the range of 20% to 24% and adjusted operating expenses to be within the range of $88 million to $93 million.“2026 is about shifting to offense while keeping this discipline intact. We will focus on moving towards profitable growth, gaining share, scaling Nexis, and investing in new high-growth adjacencies such as AI data center power. And I believe 2026 will be a transformational year for SolarEdge that will take the company to the next level,” Nir added.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around SEDG trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;One bullish user predicted that SEDG stock will hit 3 digits in 2026.<stembedurl>https://stocktwits.com/mido89/message/645226938</stembedurl>One bearish user said that stock will end Wednesday’s trading at $30 if market reacts to the ‘awful’ earnings.&nbsp;<stembedurl>https://stocktwits.com/unnconscious/message/645212388</stembedurl>Shares in the company have risen 113% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a SolarEdge Technologies logo is seen on a smartphone

Solaredge Technologies Stock Dives After Q4 Earnings, Why Is Retail Divided?

The company reported revenues of $335.4 million, down 1.4% from $340.2 million in the prior quarter.

<ul class="summary-bullets"><li>Nelson Peltz, founder of Trian Fund Management, holds a 16.24% stake in Wendy's, according to a filing.</li><li>The filing further said that Peltz could “enter into financial instruments or other agreements” with other parties to “increase or decrease” his economic exposure on that investment.&nbsp;</li><li>Peltz’s Trian Fund Management has spoken with potential financing sources, potential co-investors and certain potential strategic partners.</li></ul>Activist investor Nelson Peltz said that he is reviewing alternatives with regards to his investment in Wendy’s, as the founder of investment firm Trian Fund Management holds 16.24% stake in Wendy's, according to a filing.Shares jumped more than 14% at the time of writing.&nbsp;Peltz’s Trian Fund Management has spoken with potential financing sources, potential co-investors and certain potential strategic partners, regarding potential transactions in which such parties could participate and may benefit the company's shareholders, according to the regulatory filing.&nbsp;Peltz thinks that Wendy's stock is undervalued and said that he is considering his options that potentially involve buying more shares of the company or selling all or part of his stake.&nbsp;The filing further said that Peltz could “enter into financial instruments or other agreements” with other parties to “increase or decrease” his economic exposure on that investment.&nbsp;Peltz had considered a similar move back in 2022 but decided not to go ahead with it and opted for higher dividend and corporate restructuring. He resigned as chairman of Wendy’s board in 2024 to devote more time to his hedge fund.&nbsp;<h2 class="st-heading-2">Weak Forecast</h2>Wendy’s last week forecasted weak guidance for FY2026 that disappointed investors. The fast-food chain’s 2026 profit outlook of $0.56 to $0.60 per share fell well short of analyst expectations of $0.85 and at the time triggered selloff in the stock.&nbsp;Wendy’s fourth quarter profit of $0.16 per share scraped past analysts’ earnings of $0.15 per share. Its revenue of $543 million in the quarter also edged above analysts’ estimates of $537.5 million.&nbsp;Its global sales fell 8.3% to $3.4 billion in the quarter along with same-restaurant sales falling 10.1% globally.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around WEN trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in the company have fallen 45% over the past year.&nbsp; &nbsp;

A Wendy’s outlet in Bloomsburg, Pennsylvania, United States. 

Wendy’s Stock Jumps As Nelson Peltz Says He Is Reviewing His Investment 

Peltz thinks that Wendy's stock is undervalued and that he is considering his options that potentially involve buying more shares of the company or selling all or part of his stake. 

<ul class="summary-bullets"><li>Jefferies noted that the company delivered another strong quarter, with Vyjuvek topline U.S. revenue growth re-accelerating with robust demand, reaching about 60% penetration.&nbsp;</li><li>Krystal reported Q4 diluted earnings per share of $1.70, up from the $1.52 reported in the corresponding quarter of 2024, and above an analyst estimate of $1.47.&nbsp;</li><li>Krystal’s Vyjuvek is a gene therapy approved for the treatment of Dystrophic Epidermolysis Bullosa.</li></ul> Shares of Krystal Biotech (KRYS) rose 5% on Tuesday after Jefferies hiked its price target on the stock on the heels of the company’s fourth-quarter (Q4) earnings that beat Wall Street expectations.&nbsp; Jefferies analyst Roger Song raised the firm's price target on Krystal Biotech to $371 from $310 and kept a ‘Buy’ rating on the shares after meeting with company management, as per TheFly. The new price target represents a potential upside of about 34% from the stock’s closing price on Friday.The firm noted that the company delivered another strong quarter, with Vyjuvek topline U.S. revenue growth re-accelerating with robust demand, reaching about 60% penetration and ex-U.S. expansion likely to become a 2026 growth driver. Pipeline continues to mature, with two ophthalmology programs in pivotal trials with data in 2026, and two more nearing pivotal, Jefferies added.<h2 class="st-heading-2">Krystal’s Q4 Earnings</h2>Krystal reported Q4 diluted earnings per share of $1.70, up from the $1.52 reported in the corresponding quarter of 2024, and above an analyst estimate of $1.47, according to data from Fiscal AI.The company recorded $107.1 million in Vyjuvek net product revenue for the fourth quarter, up from $91.1 million in the corresponding quarter of 2024. Vyjuvek is a gene therapy approved for the treatment of Dystrophic Epidermolysis Bullosa, a rare, inherited genetic disorder characterized by severe skin fragility, where minimal friction causes blisters, erosions, and scarring. &nbsp;The company said that it has secured over 660 reimbursement approvals for Vyjuvek in the United States and high patient demand is driving steady Vyjuvek uptake since launch in Germany, France, and Japan.For 2026, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-fourth-quarter-and-full-year-2025">expects </a>adjusted research and development as well as selling, general and administrative expenses to add up to $175 million-$195 million, lower than the $204.7 million reported for 2025.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around KRYS stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.<a href="https://stocktwits.com/symbol/KRYS">KRYS stock</a> has gained 85% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-robotaxis-reportedly-involved-in-14-crash-incidents-since-launch/cZRWMUpR4HG">Tesla Robotaxis Reportedly Involved In 14 Crash Incidents Since Launch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Krystal Biotech logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism

Jefferies’ new price target represents a potential upside of about 34% from the stock’s closing price on Friday. 

<ul class="summary-bullets"><li>Wakix was first approved by the FDA for adult narcolepsy patients in 2019 and for pediatric narcolepsy patients in 2024.&nbsp;</li><li>Harmony has an exclusive license from France’s Bioprojet to develop, manufacture and commercialize Wakix in the United States.</li><li>According to data from Koyfin, eight of the 11 analysts covering the stock rate it ‘Buy’ or higher while two rate it ‘Hold' and one rates it a ‘Strong Sell.’</li></ul>Shares of Harmony Biosciences (HRMY) edged up 2% on Tuesday after the company announced that the U.S. Food and Drug Administration has approved its Wakix tablets for the treatment of cataplexy in pediatric patients aged 6 years and older with narcolepsy.Narcolepsy is a chronic neurological disorder, characterized by an inability to regulate sleep-wake cycles, leading to extreme daytime sleepiness, sudden sleep attacks, and potential muscle weakness, also called cataplexy.<h2 class="st-heading-2">Other Approvals For Wakix</h2>Wakix was first approved by the FDA for adult narcolepsy patients in 2019. In 2024, the agency approved it in pediatric narcolepsy patients to treat excessive daytime sleepiness. The latest approval adds to existing ones.“WAKIX is now the first-and-only FDA-approved treatment option for both pediatric and adult narcolepsy patients with or without cataplexy that is not scheduled as a controlled substance, an important distinction that supports its clinical utility,” <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.harmonybiosciences.com/news-releases/news-release-details/harmony-biosciences-receives-us-food-and-drug-administration-1">said</a> CEO Jeffrey M. Dayno.WAKIX was designed and developed by France’s Bioprojet. However, Harmony has an exclusive license to develop, manufacture, and commercialize it in the United States.<h2 class="st-heading-2">Wall Street Take</h2>According to data from Koyfin, eight of the 11 analysts covering the stock rate it ‘Buy’ or higher while two rate it ‘Hold' and one rates it a ‘Strong Sell.’The average price target on the stock is at $46.73, representing a potential upside of about 30% from the stock’s closing price on Friday.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around HRMY shares rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.<a href="https://stocktwits.com/symbol/HRMY">HRMY stock</a> has dropped nearly 6% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/cftc-mike-selig-court-fight-target-prediction-markets/cZRWoHhR4uo">CFTC Chair Warns Prediction Market Critics: ‘We’ll See You in Court’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

HRMY Stock Rises On Fresh FDA Approval For Wakix Tablets In Children But Wall Street Eyes Further Rally

The FDA has approved Harmony’s Wakix tablets for the treatment of cataplexy in pediatric patients aged 6 years and older with narcolepsy.

<ul class="summary-bullets"><li>Starboard said it is intending to nominate a highly-qualified slate of directors representing a majority of the Board.&nbsp;</li><li>Tripadvisor said its management and the Board are focused on pursuing all avenues to drive value for shareholders.</li></ul>Shares of TRIP rallied on Tuesday after it responded to a shareholder letter from Starboard value who has urged Tripadvisor to either explore sale or shake up its board.&nbsp;At the time of writing, TRIP stock was 6.5% up.&nbsp;<h2 class="st-heading-2">Starboard Value’s Letter</h2>Starboard said that it believes that Tripadvisor should be formally exploring a sale of the entire company, in one or multiple transactions. Starboard holds more than 9% stake in the company.&nbsp;Starboard in its letter to TRIP highlighted the company’s prolonged underperformance and failure to take decisive action to create shareholder value.&nbsp;“Shareholders deserve a credible, comprehensive process focused on maximizing value. If this Board cannot take decisive action in a timely manner, as it has proven time and time again, we believe it is time for meaningful change,” it said in a shareholder letter.&nbsp;&nbsp;“We have offered to work with Tripadvisor to reconstitute the Board, but it has become clear to us that we must take action into our own hands and seek to replace a majority of the Board,”&nbsp;Starboard&nbsp;added.&nbsp;Starboard said that during TripAdvisor’s upcoming window for shareholders to submit director nominations with respect to its 2026 annual meeting of shareholders, Starboard is intending to nominate a highly-qualified slate of directors representing a majority of the Board.&nbsp;<h2 class="st-heading-2">TRIP’s Response</h2>Tripadvisor said that its Board and management team regularly engage with investors and welcome constructive input that furthers the common goal of enhancing value for all shareholders.Tripadvisor will continue to take actions it believes will drive sustainable value as it executes its strategic priorities and further positions the company for long-term growth, it said in a response to the shareholder letter.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around TRIP trended in ‘neutral’ territory amid ‘extremely high’ message volume.&nbsp;Shares in the company have risen 42% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, a Tripadvisor logo is seen displayed on a smartphone. 

Why Is TRIP Stock Rallying Today?

 Starboard said that it believes that Tripadvisor should be formally exploring a sale of the entire company, in one or multiple transactions.

Are Odds Improving for a Fed Rate Cut? ETFs to Consider

Cooling inflation boosts the odds for a Fed interest rate cut in June. These ETFs can help investors ride the potential gains.

<ul class="summary-bullets"><li>Analysts at B. Riley hiked their price target for Corsair to $7 from $6, while keeping a ‘Neutral’ rating on the stock.</li><li>The firm noted Corsair’s beat across the revenue, margins, and Performance Memory sales.</li><li>However, Craig-Hallum analyst Tony Stoss pointed to Corsair’s revenue guidance of $1.4 billion for the fiscal year 2026, reflecting a year-on-year decline.</li></ul>Corsair Gaming Inc. (CRSR) shares are soaring on Friday morning, trading more than 58% higher, following the gaming brand’s fourth-quarter (Q4) earnings beat and a $50 million share repurchase program.However, Wall Street is divided about the stock’s prospects, with some firms trimming their price targets, while others have given the stock a thumbs up.Corsair reported earnings per share (EPS) of $0.43 on revenue of $437 million in Q4, while the consensus estimate was for an EPS of $0.27 on revenue of $422 million, according to TheFly.<h2 class="st-heading-2">What Are Analysts Saying?</h2>Analysts at B. Riley hiked their price target for Corsair to $7 from $6, while keeping a ‘Neutral’ rating on the stock.The firm noted Corsair’s beat across the revenue, margins, and Performance Memory sales. B. Riley said that while Corsair's preliminary 2026 guidance is cautious, the gaming company’s $50 million share repurchase program and the Q4 earnings beat highlight more positives than negatives for Corsair.However, the analysts said that the current operating conditions in the market may limit Corsair’s sustained momentum.Analysts at Barclays trimmed their price target for CRSR to $8 from $9, while keeping an ‘Overweight’ rating on the stock.Craig-Hallum analyst Tony Stoss pointed to Corsair’s revenue guidance of $1.4 billion for the fiscal year 2026, reflecting a year-on-year decline. The company reported $1.47 billion in fiscal 2025 revenue.However, the firm said that Corsair’s guidance for an increase in adjusted earnings before interest, taxes, depreciation, and amortization (AEBITDA) implies continued benefits from memory pricing, as the company focuses on higher-margin business. Craig-Hallum lowered its price target for Corsair to $8 from $10, while keeping a ‘Buy’ rating on the shares.Baird analysts also lowered their price target for Corsair to $6 from $7, while keeping a ‘Neutral’ rating on the stock.According to Koyfin data, the 12-month average price target for Corsair shares is $8.19, implying a nearly 16% upside from current levels. Of the eight analysts covering the stock, four have a ‘Strong Buy’ or ‘Buy’ rating, while the other four have a ‘Hold’ recommendation.<h2 class="st-heading-2">Corsair Says It Is Focusing On Improving Quality Of Growth</h2>The gaming company said in its announcement that it is focusing on the quality of growth by investing in platforms that can scale across its portfolio.“Successful new product launches, smart inventory management, coupled with our supply chain flexibility, enabled us to navigate a memory-constrained market, shifting trade regulations and tariffs,” said Corsair CEO Thi La.The company said that while its FY26 revenue is expected to decline 5% YoY, the Gamer and Creator Peripherals segment is expected to grow in double digits. However, it remains cautious about its Gaming Components and Systems segment due to ongoing global semiconductor shortages.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/CRSR">Corsair</a> trended in the ‘neutral’ territory. SMR stock was among the top three trending tickers on the platform at the time of writing.<a href="https://stocktwits.com/symbol/CRSR">CRSR stock</a> is up 22% year-to-date, but down 42% over the past 12 monthsAlso See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/goldman-sachs-david-solomon-warns-of-shocks-if-deficit-not-controlled/cZR5xtUR4t5">Goldman Sachs CEO David Solomon Warns Of 'Shocks' If Deficit Is Not Brought Under Control And Growth Rate Is Not Brought Up: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CRSR Stock Is Soaring Today After Corsair’s Q4 Beat, $50M Share Repurchase Program – But Wall Street Is Divided

Despite Corsair’s fourth-quarter earnings beat, some firms on Wall Street trimmed their price targets, while others have given the stock a thumbs up.

BlackRock Institutional Trust Company N.A. - iShares Core S&P Small-Cap ETF

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

Current Price	$130.18
Prev Close	$128.99
Open	$129.14
Dividend Yield	N/A
50-Day Moving Average	$126.69
Beta	N/A
Avg. Volume	6.12M
PE Ratio	N/A

52-Week High	$133.52
52-Week Low	$89.22
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

IJR
iShares Core S&P Small-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IJR News

IJRiShares Core S&P Small-Cap ETF